ATX-898 / Antares Therapeutics - LARVOL DELTA

A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=343 | Recruiting | Sponsor: Antares Therapeutics, Inc | Not yet recruiting ➔ Recruiting | Trial primary completion date: Oct 2028 ➔ Oct 2029

Enrollment open • First-in-human • Monotherapy • Platinum resistant • Trial primary completion date • Oncology • Ovarian Cancer • Solid Tumor • HER-2

A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=343 | Not yet recruiting | Sponsor: Antares Therapeutics, Inc

First-in-human • Monotherapy • New P1/2 trial • Platinum resistant • Oncology • Ovarian Cancer • Solid Tumor • HER-2

Antares Therapeutics, Inc. has registered a first-in-human Phase I/II study of ATX-898, an investigational small molecule whose molecular target has not been publicly disclosed, in patients with advanced solid tumors (AllSci Corp) - "Primary completion is projected for October 2028, with full study completion expected January 2030."

First-in-human • Trial completion date • Trial status • Solid Tumor